

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/098450 A2

(51) International Patent Classification⁷: G01N 33/574

Ehren [US/US]; Beckman Center, 279 Campus Drive, B453, Stanford, CA 94305 (US).

(21) International Application Number:

PCT/US2005/009926 ✓

(74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, CA 94303 (US).

(22) International Filing Date: 24 March 2005 (24.03.2005) ✓

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/558,953

2 April 2004 (02.04.2004) ✓ US

60/629,527

18 November 2004 (18.11.2004) ✓ US

(71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; 1705 El Camino Real, Palo Alto, CA 94306-1106 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

(72) Inventor; and

(75) Inventor/Applicant (for US only): GARBER, Mitchell,

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR USE IN EVALUATING AND TREATING NEOPLASTIC DISEASE CONDITIONS ✓



(57) Abstract: Methods and compositions for use in a evaluating and treating neoplastic disease conditions are provided. In certain embodiments of the subject invention, the presence of at least one target protein associated with cellular locomotion is determined in a cell to make an evaluation regarding the cell and/or host from which the cell was obtained. In yet other embodiments, the activity of at least one target protein, is modulated, e.g., inhibited. In certain embodiments, the target protein is part of a nucleus-associated ribbon-like structure. Also provided are kits and pharmaceutical compositions that find use in various embodiments of the subject invention. The invention finds use in a variety of different applications, including both diagnostic and therapeutic applications.

WO 2005/098450 A2

BEST AVAILABLE COPY



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*